 |
 |
South Staffordshire Joint Formulary
Cannock Chase Clinical Commissioning Group
East Staffordshire Clinical Commissioning Group
South East Staffordshire and Seisdon Peninsula Clinical Commissioning Group
Stafford and Surrounds Clinical Commissioning Group |
| Results |
Looking for Adalimumab found 30 matches
|
| Open monograph to display formulary status |
BNF Category |
| |
Adalimumab
|
Gastro-intestinal system - Cytokine inhibitors - 01.05.03
|
| |
 Adalimumab
(Humira®)
|
Musculoskeletal and joint diseases - Drugs affecting the immune response - 10.01.03
|
| |
Adalimumab
(Humira®)
|
Skin - Drugs affecting the immune response - 13.05.03
|
| |
Links Link to Drug Section  Link to document |
|
NICE TA130: Rheumatoid arthritis - adalimumab, etanercept and infliximab (10.01.03)
|
|
NICE TA143: Ankylosing spondylitis - adalimumab, etanercept and infliximab (10.01.03)
|
|
NICE TA146: Psoriasis - adalimumab (13.05.03)
|
|
NICE TA187: Infliximab and adalimumab for the treatment of Crohn’s disease (01.05.03)
|
|
NICE TA187: Infliximab and adalimumab for the treatment of Crohn’s disease (01.05.03)
|
|
NICE TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (10.01.03)
|
|
NICE TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (10.01.03)
|
|
NICE TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (10.01.03)
|
|
NICE TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (10.01.03)
|
|
NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab (10.01.03)
|
|
NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab (NICE TA199) (10.01.03)
|
|
NICE TA329 Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (01.05.03)
|
|
NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis (01.05.03)
|
|
NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis (01.05.03)
|
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (10.01.03)
|
|
NICE TA373: Juvenile idiopathic arthritis- abatacept, adalimumab, etanercept and tocilizumab (10.01.03)
|
|
NICE TA373: Juvenile idiopathic arthritis- abatacept, adalimumab, etanercept and tocilizumab (10.01.03)
|
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
|
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
|
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
|
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
|
|
NICE TA375: Adalimumab, eternecept, infliximab, certolizumabpegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
|
|
NICE TA392 Adalimumab for treating moderate to severe hidradenitis suppurativa (10.01.03)
|
|
NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (13.05.03)
|
|
NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (10.01.03)
|
|
NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (13.05.03)
|
|
TA392 Adalimumab for treating moderate to severe hidradenitis suppurativa (13.05.03)
|
|
|
|
|
|
